Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan  by Kawaguchiya, M. et al.
ORIGINAL ARTICLEEmerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae
with macrolide resistance genes in northern JapanM. Kawaguchiya1, N. Urushibara1, M. S. Aung1, S. Morimoto2, M. Ito2, K. Kudo2, A. Sumi1 and N. Kobayashi1
1) Department of Hygiene, Sapporo Medical University School of Medicine and 2) Sapporo Clinical Laboratory Inc., Sapporo, Hokkaido, JapanAbstractIn Japan, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced to the nation’s routine immunization program in April 2013
and was replaced by the 13-valent pneumococcal conjugate vaccine (PCV13) in November 2013. Distribution of serotypes and macrolide
resistance genotypes was investigated for a total of 1097 (975 children, 122 adults) and 960 (873 children, 87 adults) clinical isolates of
Streptococcus pneumoniae from noninvasive infections in Hokkaido (northern main island of Japan) in the routine immunization periods for
PCV7 and PCV13 (April–October 2013 and November 2013–November 2014, respectively). Serotype was determined by sequential
multiplex PCR and additional genetic analyses. Macrolide resistance genes erm(B) and mef(A/E) were detected by multiplex PCR.
Although the most prevalent serotypes in children were 23A and 6C in the PCV7 period, after replacement with PCV13, 19A became
the most common, followed by 6C, 15A and 23A. Among adults, serotype 3 was consistently the most frequent throughout the study
periods. Compared with values from the pre-PCV7 routine immunization period, PCV7 serotypes decreased from 48.3 to 3.3% in the
PCV13 period among children, while the rates of non-PCV13 serotypes (particularly 15A, 23A, 11A, 10A and 35B) increased from 39.7
to 75.1% (p < 0.001). In the PCV13 period, erm(B), mef(A/E) and both of these genes were detected in 75.8, 31.6 and 11.3% of all
isolates, respectively. Serotype 19A accounted for 76.9% of the isolates with both the macrolide resistance genes, and emerging non-
PCV13 serotypes 15A, 15C and 23A mostly harboured erm(B).
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: kawaguchiya@sapmed.ac.jpIntroductionStreptococcus pneumoniae (pneumococcus) is a major cause of
community-acquired infections, such as pneumonia, meningi-
tis, septicemia and otitis media worldwide, particularly in
younger children and the elderly. Among at least 95 capsular
serotypes classiﬁed for S. pneumoniae, several serotypes are
more commonly associated with infections in humans and
have been targeted by pneumococcal vaccines. To date,w Microbe and New Infect 2016; 9: 66–72
w Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice
p://dx.doi.org/10.1016/j.nmni.2015.11.001S. pneumoniae has been increasingly become resistant to an-
tibiotics represented by β-lactams and macrolides worldwide
[1]. Particularly after the introduction of the 7-valent pneu-
mococcal vaccine (PCV7) in the United States since 2000, the
increase of isolates resistant to erythromycin (macrolides) has
been noted [2,3]. Furthermore, isolates that are not suscep-
tible to at least one antimicrobial increased among nonvaccine
serotypes after the introduction of PCV7 and the 13-valent
pneumococcal conjugate vaccine (PCV13) in Ireland [4].
The PCV7 vaccine has been available for infant vaccination
programs in the United States and many other countries since
the 2000s. Since 2010, a new 13-valent pneumococcal conju-
gate vaccine (PCV13), which contains PCV7 serotypes and six
additional serotypes (1, 3, 5, 6A, 7F and 19A), has been
introduced worldwide instead of PCV7. However, non-PCV13European Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
TABLE 1. Sequential multiplex PCR scheme to determine
Streptococcus pneumoniae serotypes designed for Japanese
isolates
Reaction no. Serotypes assigned in each reaction
1 19A, 3, 22F, 6A/B/C/D
2 15B/C, 23A, 10A, 11A
3 23F, 33F, 15A, 38
4 19F, 16F, 18, 35B
5 1, 34, 35F
6 4, 14, 12F, 9V
NMNI Kawaguchiya et al. Noninvasive S. pneumoniae in northern Japan 67serotypes associated with multidrug resistance, such as 15A and
35B, were found to emerge in the PCV13 period [5].
In Japan, PCV7 was ﬁrst introduced in February 2010 as a
voluntary vaccination in children <5 years of age, and the estimated
vaccination coverage rate gradually increased up to 80–90% in
2012 [6]. Since April 2013, PCV7 had been implemented into the
routine immunization program and was replaced by the PCV13 in
November 2013. After the introduction of voluntary PCV7
vaccination for children in Japan, a decrease in the incidence of
invasive and noninvasive pneumococcal infections due to PCV7
serotypes has been observed in children and unvaccinated adults
[6,7]. Regarding vaccination for adults, a 23-valent pneumococcal
polysaccharide vaccine (PPSV23), which contains PCV13 sero-
types (except for 6A) and 12 other serotypes (2, 8, 9N, 10A, 11A,
12F, 15B, 17F, 20, 22F and 33F), was approved for routine vacci-
nation in October 2014, while PCV13 had been available for
voluntary use since June 2014 for adults 65 years of age.
The purpose of the present study was to analyse the changes
in serotypes and its relationship to macrolide resistance geno-
types among noninvasive or colonization isolates of
S. pneumoniae in northern Japan during the PCV7 and PCV13
routine immunization periods and compare it with previous
data of the PCV7 voluntary immunization period in 2011.Materials and MethodsBacterial isolates
A total of 2057 S. pneumoniae isolates from noninvasive infections
in outpatients among children (<16 years old) and adults (16
years old) who visited various hospitals and clinics throughout
Hokkaido (northernmain island of Japan)were analysed. Among all
the isolates, 1097 (975 children, 122 adults), and 960 (873 children,
87 adults) isolates were collected in the PCV7 period (April
2013–October 2013) and the PCV13 period (November
2013–November 2014), respectively. Prevalence of serotypes and
macrolide resistance genotypes in the present studywas compared
with those of our previous study in 2011 (PCV7 voluntary im-
munization period, 998 and 63 isolates from children and adults,
respectively) [8]. Bacterial isolation from clinical specimens and
species identiﬁcationwere carried out by conventional methods in
the Sapporo Clinical Laboratory, Japan, and only one isolate per
patient was analysed. The pneumococci in this study were isolated
from nasal discharges (90.3%), ear discharges (4.7%) and pharynx
or sputum (4.4%). Isolates were preserved in Microbank (Pro-Lab
Diagnostics, Richmond Hill, Canada) at −80°C until analysed.
Serotyping and macrolide resistance genotypes
Serotypes were determined by sequential multiplex PCR (SM-
PCR) with a series of combinations of serotype-speciﬁc primerNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artipairs targeted at capsular polysaccharide biosynthesis (cps) lo-
cus (Table 1), using a modiﬁed version of the scheme described
by Pai et al. [9]. The scheme in the present study was designed
to determine serotypes of Japanese isolates more conveniently,
based on serotype prevalence in our previous report [8]. The
cpsA was detected in each time of multiplex PCR (M-PCR) as
described previously [9]. For untypeable isolates after the total
six reactions of SM-PCR, uniplex PCR or M-PCR was per-
formed to assign serotypes 2, 21, 24, 7C, 7F, 8, 17F, 20 and 31
using primers described previously [8–10]. M-PCR combined
with mutagenic PCR and restriction fragment length poly-
morphism was used for discrimination of serotypes 6A, 6B, 6C
and 6D as described previously [8]. Genotype 6E was detected
by M-PCR as described previously for all the isolates assigned to
6A and 6B [11]. The macrolide resistance genes erm(B) and
mef(A/E) were detected by M-PCR using primers described
previously [12,13]. Serotypes 15B and 15C were identiﬁed by
PCR and direct sequencing of partial wciZ as previously
described [8], after detection of 15B/C by SM-PCR.
Statistical analysis
Statistical analysis was performed by SPSS 19.0 (IBM, Armonk,
NY, USA). A two-tailed chi-square test or Fisher’s accurate
probability methods (for small group sizes) was used to
examine the signiﬁcance in the changes of serotypes during the
study periods. A p value of <0.05 was considered statistically
signiﬁcant.ResultsPrevalence of serotypes
Among the total of 2057 isolates, serotype was determined for
2053 isolates (99.8%) by SM-PCR. Detection rates of individual
serotypes in children and adults in the three periods (pre-PCV7,
PCV7 and PCV13 routine immunization periods) are shown in
Figs. 1 and 2, respectively, and frequencies of serotypes are
summarized in Supplementary Table S1. In the PCV7 period, the
common serotypes were 23A (15.0%), followed by 6C (13.6%),lf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 9, 66–72
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
FIG. 1. Serotype distribution of Streptococcus pneumoniae among children in the pre-PCV7, PCV7 and PCV13 routine immunization periods. Serotypes
included in PCV7 and PCV13 are indicated by blue and red arrows, respectively. NT, nontypeable; PCV, pneumococcal conjugate vaccine.
68 New Microbes and New Infections, Volume 9 Number C, January 2016 NMNI19A (8.4%), 15C (8.0%) and 15A (7.3%) in children and were 3
(17.2%), 19F (13.9%) and 19A (12.3%) in adults. In the PCV13
period, the prevailing serotypes were 19A (15.3%), 6C (14.2%),
15A (11.8%) and 23A (11.2%) in children and were 3 (14.9%), 6C
(12.6%), 19A (10.3%), 6B and 35B (each 9.2%) in adults.
Compared to our previous data in 2011 (pre-PCV7 period)
to the PCV13 period in 2013–2014, a signiﬁcant increase wasFIG. 2. Serotype distribution of Streptococcus pneumoniae among adults in the
Green arrow indicates serotypes included in PPSV23. PCV, pneumococcal co
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceobserved for serotype 19A (from 3.2 to 15.3%, p < 0.001), 15A
(from 0.9 to 11.8%, p < 0.001), 23A (from 4.5 to 11.2%,
p < 0.001) and 11A (from 2.5 to 8.5%, p < 0.001); similarly, an
increase was also evident for serotypes 10A (from 1.9 to 5.5%)
and 35B (from 1.7 to 5.4%) in children. In contrast, PCV7 se-
rotypes decreased from 48.3% in 2011 to 3.3% in 2013–2014
(p < 0.001).pre-PCV7, PCV7 and PCV13 routine immunization periods (see Fig. 1).
njugate vaccine.
European Society of Clinical Microbiology and Infectious Diseases, NMNI, 9, 66–72
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TABLE 2. Comparison of macrolide resistance genotypes of Streptococcus pneumoniae isolates in three periods by age
Macrolide resistance
genotype
Noninvasive S. pneumoniae isolates, n (%), for:
Pre-PCV7 routine immunization
period (previous study in 2011)
PCV7 routine immunization period
(April–October 2013)
PCV13 routine immunization period
(November 2013–November 2014
All ages
(n [ 1061)
<16 years
(n [ 998)
‡16 years
(n [ 63)
All ages
(n [ 1097)
<16 years
(n [ 975)
‡16 years
(n [ 122)
All ages
(n [ 960)
<16 years
(n [ 873)
‡16 years
(n [ 87)
erm(B)+ 704 (66.4) 671 (67.2) 33 (52.4) 807 (73.6) 711 (73.0) 96 (78.7) 721 (75.1) 653 (74.8) 68 (78.2)
mef (A/E)+ 424 (40.0) 396 (39.7) 28 (44.4) 307 (28.0) 278 (28.5) 29 (23.8) 303 (31.6) 282 (32.3) 21 (24.1)
erm(B)+ and mef(A/E)+ 113 (10.7) 109 (10.9) 4 (6.3) 79 (7.2) 70 (7.2) 9 (7.4) 108 (11.3) 100 (11.5) 8 (9.2)
erm(B)+ and mef(A/E)− 591 (55.8) 562 (56.3) 29 (46.0) 728 (66.4) 641 (65.7) 87 (71.3) 613 (63.9) 553 (63.3) 60 (69.0)
erm(B)− and mef(A/E)+ 311 (29.3) 287 (28.8) 24 (38.1) 228 (20.8) 207 (21.3) 20 (16.4) 195 (20.3) 182 (20.8) 13 (14.9)
erm(B)− and mef(A/E)− 46 (4.3) 40 (4.0) 6 (9.5) 62 (5.7) 56 (5.7) 6 (4.9) 44 (4.6) 38 (4.4) 6 (6.9)
PCV, pneumococcal conjugate vaccine.
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most frequent throughout the study periods. Compared with
2011, PCV13 serotypes 19F and 23F, and PPSV23 serotypes
11A and 15B decreased in the PCV13 period, while an increase
was observed for non-PCV13 serotypes 6C (7.9 to 12.6%,
p = 0.434), 15A (0 to 4.6%, p = 0.143), 15C (1.6 to 4.6%,
p = 0.405), and 35B (3.2 to 9.2%, p = 0.197). PCV13 serotypes
1, 5 and 7F were not detected in any periods.
Overall, from 2011 (pre-PCV7 routine immunization) to
2013–2014 (PCV13 period), PCV7- and PCV13-associated se-
rotypes in children decreased from 48.3 to 3.3% and 60.3 to
24.9%, respectively (p < 0.001). Similarly in adults, decrease of the
PCV7, PCV13 and PPSV23 types was found (34.9 to 20.7%, 60.3
to 49.4% and 85.7 to 63.2%, respectively). Consequently, the
percentage of non-PCV13 serotypes in the all ages increased
from 39.7% in 2011 to 72.9% in the PCV13 period (p < 0.001).FIG. 3. Comparison of macrolide resistance genotypes in non-PCV7 serotype
vaccine.
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artiPrevalence of macrolide resistance genotypes
Macrolide resistance genotypes in the three different periods
are summarized in Table 2. During the PCV13 period, the
macrolide resistance genes erm(B), mef(A/E) and both of these
genes were detected in 74.8, 32.3 and 11.5% of isolates in
children, respectively, and similar rates were evident in adults.
Compared with the pre-PCV7-routine immunization period,
the proportion of mef(A/E) decreased from 40.0 to 31.6% in all
ages in the PCV13 period. In contrast, the rate of isolates
carrying erm(B) increased from 66.4 to 75.1%.
The distribution of macrolide resistance genotypes in indi-
vidual serotypes during the PCV13 period in children and adults
is presented in Supplementary Figs S1 (Supplementary Table S2)
and S2 (Supplementary Table S3), respectively, and comparison
of the genotypes among non-PCV7 serotypes in children is
shown in Fig. 3. During the PCV13 period, erm(B) was carrieds in three study periods among children. PCV, pneumococcal conjugate
lf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 9, 66–72
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70 New Microbes and New Infections, Volume 9 Number C, January 2016 NMNIby all isolates of non-PCV13 serotypes 15A, 15B, 23A, 24 and
33F in children, accounting for 27.9% (244/873). Most of
serogroup 15 (serotypes 15A, 15B and 15C) isolates harboured
erm(B) (99.5%, 197/198), while only one isolate harboured
mef(A/E) solely. Presence of mef(A/E) solely was found at
highest rate in 11A (79.7%, 59/74), followed by 6C (47.6%, 59/
124) and 35B (23.4%, 11/47). All the isolates of serotypes 6B,
19F, 23F, 3, 19A, 22F and 38 carried erm(B) and/or mef(A/E)
genes. Isolates harbouring both the genes (100 isolates) mostly
belonged to serotypes 19A (79%), 11A (8%) and 6C (5%).
Among adults, all the isolates of the serotype 3 harboured
erm(B) solely in the PCV13 period (Supplementary Table S3).DiscussionIn Japan, after the introduction of PCV7, a distinct reduction of
incidence was observed for pediatric meningitis due to pneu-
mococcus (decrease by 80%, from 2009 to 2012) [14], and
nonmeningitis invasive pneumococcal disease (IPD) (decrease
by 52% from 2008–2010 to 2012) [7]. Accordingly, patients
with IPD due to PCV7 serotypes also decreased from 73.3% in
2010 to 14.7% in 2012 [6]. Similarly, the coverage rate of PCV7
serotypes for pediatric noninvasive isolates was reported to
have decreased signiﬁcantly, from 49.3% (2008–2009) to 23.4%
(2011–2012) in the Tokai region (the Paciﬁc Ocean side of
central Honshu Island), Japan [15]. However, the trend of
pneumococcal serotypes after replacement by PCV13 (i.e. since
November 2013) had not been clariﬁed.
Our present study, conducted in Hokkaido, Japan, elucidated
a change in serotypes from the pre-PCV7 routine immunization
period (2011) until the initial 1-year period of PCV13
(November 2013–November 2014), revealing evident
decrease of PCV7- and PCV13-associated serotypes in both
children and adults. In contrast, non-PCV13 serotypes
increased signiﬁcantly when the pre-PCV7 period and the
PCV13 period are compared. Similar ﬁndings have been re-
ported in studies in the the United States [16,17]. However, it
was noteworthy in the present study that serotype 19A, which
is included in PCV13, exhibited increase in the PCV13 period
compared with the PCV7 period. Serotype 19A is known to
have emerged as the predominant cause of both IPD and non-
IPD globally after the introduction of PCV7, but its prevalence
in pneumococcal infections among children has decreased by
replacement of PCV13 [4,18–20]. While increase of serotype
19A stopped immediately after introduction of PCV13 in the
United States [16], incidence of serotype 19A in IPD of adults
decreased 2.5 years after the PCV13 national immunization in
children in Israel [21]. The PCV13 period of our present study
was the initial 1-year period after switching to PCV13 fromNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licePCV7, i.e. the early PCV13 period. Therefore, the serotype
distribution in this period is considered to be still inﬂuenced by
routine immunization of PCV7, causing a high incidence of
serotype 19A. However, 19A may be predicted to decrease
shortly because the use of PCV13 has been becoming estab-
lished. In contrast, a slight decrease of other PCV13 serotypes,
such as 3 and 6A, was observed in the PCV13 period among
children in the present study. This ﬁnding suggests that these
serotypes might be prevented by PCV13 more effectively than
19A; otherwise they might not spread selectively by the use of
PCV7.
Serotype 19A has been recognized as a multidrug-resistant
type in the United States [22–24] and Europe during the
PCV7 era [25,26]. Also in Japan, as demonstrated in the present
study, serotype 19A emerged as a dominant serotype after
PCV7 introduction, showing the highest rate of isolates with
both erm(B) and mef(A/E) among all the serotypes. Similarly, a
high prevalence of these macrolide resistance genes in serotype
19A pneumococci was described in the United States, Europe
and Asia (Taiwan) [27–30], furthermore, macrolide-resistant
pneumococci carrying both resistance genes were associated
with multidrug resistance [31,32]. Thus, it is possible that such
drug resistance traits of serotype 19A may be one of the rea-
sons for persistence of this serotype even after introduction of
PCV13.
In the present study, after implementation of routine im-
munization of PCV13 in Japan, 72.9% of pneumococcal isolates
from non-IPD were revealed to belong to nonvaccine sero-
types, represented by 6C, 15A, 23A, 11A, 10A and 35B, among
which 6C, 11A, 15A and 35B appeared to have increased
gradually since the introduction of PCV7 in children. These
nonvaccine serotypes have been also described as being the
common types among isolates from IPDs, non-IPDs, and car-
riage after introduction of PCV13 as well as PCV7 in other
countries [16,20,33–36]. Particularly serotypes 15A, 6C and
35B were reported to be major multidrug resistance serotypes
in the United States [37]. Of note, in European countries, non-
PCV13 serotypes 11A and 35B among IPD isolates were
documented to be statistically associated with the risk of death
[38]. Consequently, ongoing increase of nonvaccine serotypes
is a matter of concern after the use of pneumococcal vaccines
worldwide.
The macrolide resistance genes erm(B) and/or mef(A/E)
were detected at a high rate (>95%) among invasive and
noninvasive pneumococci in Japan [8,39], a ﬁnding also shown
in the present study. In the United States, macrolide resistance
mediated by erm(B) and/or mef(A/B) was found to increase
after the introduction of PCV7, mainly as a result in the increase
of serotype 19A [29,40], while the highest erm(B)-positive rate
(100%) was seen in serotype 15A in Hong Kong [36]. OurEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 9, 66–72
nses/by-nc-nd/4.0/)
NMNI Kawaguchiya et al. Noninvasive S. pneumoniae in northern Japan 71present study also showed that the non-PCV13 types 15A, 15C
and 23A among children were mostly positive for erm(B)
(99.6%). Compared to our previous study in 2011, the erm(B)-
positive rate in non-IPD isolates in the PCV13 period increased,
associated with an increasing trend of non-PCV7 serotypes,
despite the high proportion of erm(B) in the PCV7 serotypes,
such as 6B, 19F and 23F, which has decreased by PCV7.
Therefore, the high rate of erm(B) has still persisted after the
use of pneumococcal vaccines.
In conclusion, our results in northern Japan revealed the
increase of non-PCV7/PCV13 serotypes among non-IPD iso-
lates after implementation of PCVs in Japan, associated with
high prevalence of erm(B). Our only exceptional ﬁnding was an
increase of serotype 19A in the early PCV13 period. Further
continuous surveillance on serotypes and antimicrobial resis-
tance is thus necessary for 19A and several non-PCV13 sero-
types, such as 6C, 10A, 11A, 15A, 23A and 35B.AcknowledgementSupported by a Grant-in-Aid for Scientiﬁc Research
(KAKENHI) (26893212) from the Japan Society for Promotion
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